Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management
Open Access
- 5 May 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Abstract
The unprecedented progress in addressing unmet needs in haemophilia care to date includes developing several novel therapies that rebalance haemostasis by restoring thrombin generation in patients with haemophilia A or B with and without inhibitors. These novel therapies are FVIII mimetics, antithrombin interference RNA therapy and several monoclonal antibodies directed against the tissue factor pathway inhibitor (anti-TFPI). In this review, we provide an update on the progress made in developing anti-TFPI therapie. Phase 1 data from the three anti-TFPI studies showed acceptable safety profiles, and currently, available phase 2 data are encouraging. While these data support these molecules' further development progression, there is uncertainty on several aspects of their evolution. Two of the three anti-TFPIs have shown drug-related thrombosis, with one study consequently terminated. None of the thrombotic events is predictable with current monitoring tools, and none correlate with known coagulation parameters. All three anti-TFPIs undergo target mediated drug disposition, which impacts the formulation of dosing regimen fo these therapies. They would require more frequent dosing than some of the extended half-life clotting factor products and antithrombin RNAi therapy. There is no assay to measure the TFPI as the physiological levels are very low, which makes monitoring the impact of the anti-TFPI a challenge. The anti-TFPIs have several advantages, including their bioavailability when administered subcutaneously, their stable pharmacokinetics and their ability to prevent bleeds in haemophilia A or B patients with and without inhibitors. Whether these advantages can be realized will depend on the outcome of the currently ongoing studies.Keywords
This publication has 28 references indexed in Scilit:
- Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti–Tissue Factor Pathway Inhibitor Antibody, PF-06741086Journal of Pharmaceutical Sciences, 2018
- Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus MonkeysThe AAPS Journal, 2017
- Treatment burden, haemostatic strategies and real world inhibitor screening practice in non‐severe haemophilia ABritish Journal of Haematology, 2017
- Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicityJournal of Thrombosis and Haemostasis, 2015
- Comment on: Khair K. Compliance, concordance and adherence: what are we talking about? Haemophilia Sept 2014;20(5):601–3.Haemophilia, 2015
- Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trialJournal of Thrombosis and Haemostasis, 2015
- Half-life extension technologies for haemostatic agentsThrombosis and Haemostasis, 2015
- Studies on the mechanism of action of the aptamer BAX499, an Inhibitor of tissue factor pathway inhibitorThrombosis Research, 2012
- Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia modelBlood, 2012
- Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasmaJournal of Thrombosis and Haemostasis, 2012